Article citationsMore>>

Sato, N., Fukushima, N., Maehara, N., Matsubayashi, H., Koopmann, J., Su, G.H., Hruban, R.H. and Goggins, M. (2003) SPARC/Osteonectin Is a Frequent Target for Aberrant Methylation in Pancreatic Adenocarcinoma and a Mediator of Tumor-Stromal Interactions. Oncogene, 22, 5021-5030.
https://doi.org/10.1038/sj.onc.1206807

has been cited by the following article:

• TITLE: SPARC Expression as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma

  AUTHORS: Jianxing Zhang, Peiyu Ji, Xin Fan, Xiaoyan Ma, Xuqing Wang, Zhengfa Mao

  KEYWORDS: Pancreatic Adenocarcinoma, SPARC, Prognosis, Surgery

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.8 No.4, April 11, 2018

  ABSTRACT: Background: The aim is to investigate whether secreted protein acidic and rich in cysteine (SPARC) expression could be considered as an independent prognostic factor in pancreatic ductal adenocarcinoma (PDAC). Methods: The expression of SPARC in the tumor species was detected by immunochemistry and the effect of SPARC on the prognosis was analyzed by Kaplan-Meier and Cox proportional hazard models. Results: Positive SPARC expressions recognized in tumor and stroma were 31.33% and 64.66% respectively. The expression of SPARC in stroma was closely correlated with differentiation, vascular invasion and was an indicator for predicting poor outcome after surgery in Kaplan-Meier analysis. Univariate analysis and multivariate analysis showed the following factors to be significant: perineural invasion (HR = 2.098, 95% CI: 1.144 - 3.847) and stroma positive expression of SPARC (HR = 2.120, 95% CI: 1.307 - 3.440). Conclusions: High expression of SPARC in stroma was a promising pathological marker to predict the poor outcome in patients with pancreatic ductal adenocarcinoma.